EurekaMag
+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Tabanidae
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

Antibody therapy for multiple myeloma: novel approaches and future perspectives


Antibody therapy for multiple myeloma: novel approaches and future perspectives



Japanese Journal of Clinical Hematology 61(8): 912-921



ISSN/ISBN: 0485-1439

PMID: 32908055

Although multiple myeloma has been defined as incurable, and the treatment outcome has recently improved rapidly. Antibodies against multiple myeloma, elotuzumab, and daratumumab can safely enhance their effects even when added to the combination therapy of proteasome inhibitors and immunomodulators that have been used till date. Initially, triplet therapy combining antibody therapy with doublet therapy was approved in Japan for relapsed or refractory multiple myeloma. In 2019, daratumumab combination therapies were approved for newly diagnosed multiple myeloma patients, and these therapies are the new standard of care. Recently, the results of clinical trials that added daratumumab to the triplet therapies of proteasome inhibitors, immunomodulators, and dexamethasone have been reported. These trials report greater therapeutic effects, with a significant improvement in the MRD negative rate. We hope that quadruplet therapy including these antibodies will be available in clinical practice, leading to further improvements in the treatment outcomes.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 071286152

Download citation: RISBibTeXText

Related references

State of the art therapy in multiple myeloma and future perspectives. European Journal of Cancer 42(11): 1591-1600, 2006

State of the art therapy in multiple myeloma and future perspectives. European Journal of Cancer (1990) 42(11): 1591-1600, 2006

Current and future approaches to therapy for multiple myeloma. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(1): 9-15, 1995

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. International Journal of Hematology 92(1): 52-57, 2010

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 103(2): 197-211, 2018

Antibody-Based Treatment Approaches in Multiple Myeloma. Current Hematologic Malignancy Reports 16(2): 183-191, 2021

Multiple myeloma: current status and future perspectives. Zhonghua Xue Ye Xue Za Zhi 32(10): 649-651, 2011

Bisphosphonates in multiple myeloma: current status; future perspectives. British Journal of Haematology 93(3): 501-506, 1996

Bendamustine in the treatment of multiple myeloma: Results and future perspectives. Seminars in Oncology 30(4): 23-26, 2003

Bendamustine in the treatment of multiple myeloma: results and future perspectives. Seminars in Oncology 29(4 Suppl 13: 23-26, 2002

Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncology 8(10): 1223-1238, 2012

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. Journal of Clinical Medicine 9(7), 2020

Proteomic analysis of multiple myeloma: current status and future perspectives. PROTEOMICS. Clinical Applications 5(1-2): 30-37, 2011

Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. American Journal of Blood Research 1(1): 22-33, 2011

Approaches and Challenges in the Management of Multiple Myeloma in the very Old: Future Treatment Prospects. Frontiers in Medicine 8: 612696, 2021